Table IV.
Factors predicting survival of patients
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| PFS | OS | PFS | OS | |
| Lines of therapy (≤2 versus >2 lines) | ||||
| HR | 1.01 | 0.4032119 | 1.68 | 0.37 |
| P | 0.965 | 0.266 | 0.31 | 0.30 |
| 95% CI | 0.43-2.39 | 0.081-1.99 | 0.60-4.72 | 0.059-2.40 |
| Regimen (non-pazopanib versus pazopanib) | ||||
| HR | 0.74 | 1.04 | 0.55 | 1.77 |
| P | 0.516 | 0.95 | 0.27 | 0.51 |
| 95% CI | 0.31-1.78 | 0.26-4.16 | 0.18-1.60 | 0.31-10.16 |
| ORR (responders versus non-responders) | ||||
| HR | 0.43 | 0.10 | 0.609855 | 0.19 |
| P | 0.043 | 0.038 | 0.481 | 0.264 |
| 95% CI | 0.19-0.97 | 0.013-0.88 | 0.15-2.41 | 0.01-3.49961 |
PFS, progression-free survival; HR, hazard ratio